Last updated: May 13, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07360119 | — | Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors | Unknown mechanism |
| NCT04389632 | 1 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | B7-H6 -- antibody-drug conjugate (Sigvotatug vedotin) + PD-1 -- immune checkpoint inhibitor (Pembrolizumab) + Chemotherapy (Cisplatin, Carboplatin) |
| NCT05968326 | 2 | A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC | Neoantigens -- personalized mRNA tumor vaccine plus PD-L1 blockade |
| NCT07578337 | 2 | A Randomized Phase II Study of Priming Treatment With the Hedgehog Inhibitor NLM-001 Prior to Gemcitabine/Nab-Paclitaxel (GNab-P) plusBotensilimab and Balstilimab (Bot/Bal) Versus GNab-P in Patients With Previously Untreated Advanced Pancreatic Cancer (NUMANTIA-2) | Hedgehog pathway -- small molecule inhibitor (NLM-001); PD-1 + CTLA-4 -- dual immune checkpoint blockade (Botensilimab and Balstilimab) |
| NCT05086250 | 1 | Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer | NMDA receptor -- antagonist (small molecule) |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 21 |
| Zhejiang University | 14 |
| Tianjin Medical University Cancer Institute and Hospital | 12 |
| Ruijin Hospital | 11 |
| M.D. Anderson Cancer Center | 10 |
Countries with the most active trial sites for pancreatic cancer. A multi-site trial is counted once per country.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Sep 30, 2026 | NCT07394205 | Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer | CLDN18.2 -- CAR-T cell therapy |
| Jul 1, 2026 | NCT07377526 | Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer | TROP2-targeted CAR NK cells with IL-15 expression and TGFBR2 knockout + HIF-2α inhibition (Belzutifan) |
| Jul 2026 | NCT07153289 | CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa) | CD318 -- CAR-T cell therapy targeting CD318 |
| Jun 1, 2026 | NCT07488884 | Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer | IL-15 receptor agonist (Nogapendekin Alfa Inbakicept) + B7-H3 targeting bispecific antibody (Sotevtamab) + HDAC inhibitor (Zabadinostat) |
| May 1, 2026 | NCT07553793 | Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients | c-MET -- CAR-macrophage therapy |
| May 1, 2026 | NCT07566897 | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors | IL-2 + JAK1/2 -- immunocytokine + JAK inhibitor |
| May 2026 | NCT07444541 | ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer | CLDN18.2 -- monoclonal antibody |
| Apr 2026 | NCT07539155 | Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer | Measles, mumps, rubella virus antigens -- intratumoral vaccine |
Want trials matched to a specific patient profile?
Enter biomarkers, stage, and prior treatments — get ranked trial matches with eligibility breakdown in minutes.
Find Matching TrialsSource: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.